Alcon Inc.
SWX:ALC Rapport sur les actions
Capitalisation boursière : CHF 38.2b
Alcon Résultats passés
Passé contrôle des critères 5/6 Alcon a connu une croissance annuelle moyenne de ses bénéfices de 65.3%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 10.6% par an. Les revenus ont augmenté de en hausse à un taux moyen de 7.2% par an. Le rendement des capitaux propres de Alcon est 5.4% et ses marges nettes sont de 11.9%.
Informations clés
65.3%
Taux de croissance des bénéfices
65.2%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie 11.1% Taux de croissance des recettes 7.2% Rendement des fonds propres 5.4% Marge nette 11.9% Dernière mise à jour des bénéfices 30 Sep 2024
Mises à jour récentes des performances passées
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 13
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 21
First quarter 2024 earnings: EPS exceeds analyst expectations May 14
Full year 2023 earnings: EPS exceeds analyst expectations Feb 28
Third quarter 2023 earnings: EPS exceeds analyst expectations Nov 15
Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022) Aug 16
Afficher toutes les mises à jour
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 13
Alcon Inc. Revises Earnings Guidance for the Year 2024 Nov 13
Subdued Growth No Barrier To Alcon Inc.'s (VTX:ALC) Price Nov 11
Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens Nov 07
Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger Oct 28
Do Alcon's (VTX:ALC) Earnings Warrant Your Attention? Oct 15
CEO & Director notifies of intention to sell stock Sep 15
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Sep 04
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 21 Alcon Inc. Maintains Earnings Guidance for the Year 2024
Now 24% undervalued Aug 03
Investor Optimism Abounds Alcon Inc. (VTX:ALC) But Growth Is Lacking Jul 27
A Look At The Fair Value Of Alcon Inc. (VTX:ALC) Jul 13
Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance Jun 24
Should You Be Adding Alcon (VTX:ALC) To Your Watchlist Today? Jun 24
Alcon's (VTX:ALC) Returns On Capital Are Heading Higher Jun 10
These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well May 28
First quarter 2024 earnings: EPS exceeds analyst expectations May 14
Upcoming dividend of CHF0.24 per share May 10
Alcon Inc. Approves Gross Dividend May 09
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery Apr 30
Dividend of CHF0.24 announced Apr 10
Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit Apr 03
Alcon Announces Management Changes Mar 27
Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors Mar 21
Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India Mar 12
President of North America notifies of intention to sell stock Mar 03
Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Mar 01 Alcon Inc. Proposes Dividend for the Year 2023
Full year 2023 earnings: EPS exceeds analyst expectations Feb 28
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Feb 15
Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye Jan 10
Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price Dec 22
Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC) Dec 04
Alcon Inc., Annual General Meeting, May 08, 2024 Dec 02
Alcon Inc. Revises Earnings Guidance for the Full Year 2023 Nov 17
Third quarter 2023 earnings: EPS exceeds analyst expectations Nov 15
Calculating The Fair Value Of Alcon Inc. (VTX:ALC) Nov 08
Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023 Oct 31
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Oct 18
Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia Oct 11
Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger Aug 25
Alcon Inc. Raises Earnings Guidance for the Full Year 2023 Aug 17
Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022) Aug 16
A Look At The Fair Value Of Alcon Inc. (VTX:ALC) Aug 10
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Jul 05
Head of Corporate Development notifies of intention to sell stock May 15
Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist May 12
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Alcon Inc. Provides Earnings Guidance for the Year 2023 May 10
Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting May 07
Alcon Inc. Approves Dividend May 06
Upcoming dividend of CHF0.21 per share at 0.3% yield May 03
Does Alcon (VTX:ALC) Have A Healthy Balance Sheet? Apr 03
Full year 2022 earnings: EPS misses analyst expectations Feb 28
Now 21% undervalued Feb 24
Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices Feb 13
Alcon Launches New Total Toric Lenses for Astigmatic Patients Feb 03
Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors Feb 03
Returns Are Gaining Momentum At Alcon (VTX:ALC) Jan 19 Alcon Inc., Annual General Meeting, May 05, 2023 Jan 10
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism Jan 05
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Dec 18
Now 20% undervalued Nov 29
Alcon Inc. Updates Earnings Guidance for the Year 2022 Nov 17
Insufficient new directors Nov 16
Alcon Inc. Revises Revenue Guidance for 2022 Nov 16
Do Alcon's (VTX:ALC) Earnings Warrant Your Attention? Nov 02
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022 Sep 30
Alcon's (VTX:ALC) Returns On Capital Are Heading Higher Sep 30
We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt Sep 11
With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For Aug 26
Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million. Aug 24
Consensus forecasts updated Aug 16
Second quarter 2022 earnings: EPS exceeds analyst expectations Aug 10 Alcon Inc. Revises Revenue Guidance for 2022
These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well Jun 10
Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million. May 23
Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital May 20
Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022 May 12
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 11 Alcon Inc. Declares Dividend for 2021
Insufficient new directors Apr 27
Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery Apr 24
Alcon Inc. Announces Launch of Clareon Portfolio in the U.S Mar 08
Consensus EPS estimates increase by 12% Feb 24
Full year 2021 earnings: EPS exceeds analyst expectations Feb 16 Alcon Inc. Proposes Dividend
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital Feb 13 Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe
Ventilation des recettes et des dépenses
Comment Alcon gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes SWX:ALC Recettes, dépenses et bénéfices (USD Millions ) Date Recettes Les revenus Dépenses G+A Dépenses de R&D 30 Sep 24 9,761 1,161 3,242 860 30 Jun 24 9,636 1,102 3,231 836 31 Mar 24 9,562 1,048 3,226 842 31 Dec 23 9,455 974 3,209 845 30 Sep 23 9,274 450 3,177 837 30 Jun 23 9,085 362 3,141 795 31 Mar 23 8,880 341 3,112 759 31 Dec 22 8,717 335 3,068 723 30 Sep 22 8,695 571 3,131 684 30 Jun 22 8,657 457 3,145 706 31 Mar 22 8,550 460 3,125 703 31 Dec 21 8,291 376 3,076 703 30 Sep 21 8,082 332 2,980 706 30 Jun 21 7,818 183 2,884 680 31 Mar 21 6,922 -390 2,690 665 31 Dec 20 6,833 -531 2,694 675 30 Sep 20 6,806 -717 2,647 678 30 Jun 20 6,836 -636 2,662 702 31 Mar 20 7,525 -604 2,827 707 31 Dec 19 7,508 -656 2,802 690 30 Sep 19 7,386 -638 2,830 735 30 Jun 19 7,280 -779 2,827 688 31 Mar 19 7,177 -362 2,761 665 31 Dec 18 7,153 -227 2,799 653 30 Sep 18 7,123 175 2,725 527 31 Dec 17 6,792 256 2,596 545 31 Dec 16 6,596 -170 2,526 481 31 Dec 15 6,776 308 2,337 457
Des revenus de qualité: ALC a des bénéfices de haute qualité .
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de ALC sont plus élevées que l'année dernière ALC. (11.9%) sont plus élevées que l'année dernière (4.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ALC est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 65.3% par an.
Accélération de la croissance: La croissance des bénéfices de ALC au cours de l'année écoulée ( 158% ) dépasse sa moyenne sur 5 ans ( 65.3% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices ALC au cours de l'année écoulée ( 158% ) a dépassé celle du secteur Medical Equipment 2.9%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de ALC ( 5.4% ) est considéré comme faible .
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
